comparemela.com

Latest Breaking News On - Miguel regueiro - Page 1 : comparemela.com

Meet the leaders of the top 5 GI hospitals in the US

Discover the top physicians leading the GI departments at the five best hospitals for gastroenterology in the U.S., according to Newsweek s 2024 rankings.

New-york
United-states
Massachusetts
Boston
Rochester
Pbruce-sands
James-hamilton
Darrell-pardi
Miguel-regueiro
Wolfram-goessling
Best-specialized

Sequence Study of Risankizumab vs Ustekinumab in CD

David Rubin, MD, leads the panel discussion on a head-to-head sequence study of rizankizumab vs ustekinumab in the treatment of CD, as well as approaches to choosing first-line treatment.

Marla-dubinsky
David-rubin
Miguel-regueiro
Remo-panaccione
Sara-horst
Crohn-x27s-disease
Cd
Il-12
Il-23
Sequence
Bustekinumab

Use of Upadacitinib in Treatment of CD

Remo Panaccione, MD, FRCPC, provides an overview of the newest oral therapy approved for CD, upadacitinib.

Canada
David-rubin
Miguel-regueiro
Sara-horst
Remo-panaccione
Marla-dubinsky
Crohn-x27s-disease
Cd
Upadacitnib
Jak-inhibitors

Selecting CD Treatment in Special Scenarios

Experts in gastroenterology discuss treatment selection in special situations of CD, such as age, women considering pregnancy, and extra-intestinal manifestations.

Remo-panaccione
Sara-horst
Miguel-regueiro
David-rubin
Marla-dubinsky
Crohn-x27s-disease
Cd
Treatment-selection
Scenarios
Pregnancy
Extra-intestinal-manifestations

Treat-to-Target in CD

Miguel Regueiro, MD, and David Rubin, MD, review the treat-to-target strategy in relation to CD management, and how treat-to-target moves beyond symptom control.

Marla-dubinsky
Remo-panaccione
Sarah-horst
David-rubin
Miguel-regueiro
Crohn-x27s-disease
Cd
Treat-to-target
Stride
Biomarkers
Endoscope

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.